2014 Multiple Myeloma Debate

Dr Pieter Sonneveld, Prof Michele Cavo, Dr Jesus San Miguel and Dr Meletios Dimopoulos discuss the highlights from the Multiple Myeloma Debate in Copenhagen The panel discusses the most recent data presented on: Current and emerging treatment paradigms: Choice between sequential or combination therapy for MM The role of new therapies such as pomalidomide Role of carfilzomib plus melphalan and prednisone as the upfront therapy of elderly patients with MM New agents, such as MLN-9708, (an oral proteasome inhibitor), and daratumumab (an anti-CD38 monoclonal antibody) Relapsed MM: Defining the correct sequence of novel agents in the treatment of relapsed MM Recognising and responding to resistance in relapsed MM Primary refractory or multiply-relapsed MM: What are our options? Transplantation: The role of allotransplant in the era of novel therapies How salvage autologous stem cell transplantation (ASCT) can achieve sustained disease control in recurrent MM Optimal pre-transplant therapy Best practice for post transplantation consolidation and maintenance therapy This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Prof Robin Foa, Dr Simon Rule and Dr Clemens Wendtner discuss the main highlights presented from the ASH 2013 meeting. The participants discuss recent treatment advances in CLL and MCL and how this could impact on future treatment practices.